Designing pH-Triggered Drug Release Iron Oxide Nanocomposites for MRI Guided Photothermal-Chemoembolization Therapy of Liver Orthotopic Cancer

Fengyong Liu,∗a Xin Li,a Yangyang Li,∗bc Yuchen Qi,c Hongjun Yuan,a Jian He,c Wanlin Li,c and Min Zhou∗bcd

a Department of Interventional Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
b Department of Nuclear Medicine & Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
c Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China
d State Key Laboratory of Modern Optical Instrumentations, Zhejiang University, Hangzhou 310058, China

E-mail addresses: zhoum@zju.edu.cn (Min Zhou); fengyongliu@aliyun.com (Fengyong Liu); 11526010@zju.edu.cn (Yangyang Li)
Figure S1 (a) DLS size distribution of hematite nanoparticles after PDA modification and DOX loading process. (b) Zeta potentials of Fe$_2$O$_3$, Fe$_2$O$_3$@PDA, DOX molecules and Fe$_2$O$_3$-PDA-DOX, respectively.
**Figure S2** Relative cell viability of N1S1 hepatoma cell incubated with PDA coated Fe$_2$O$_3$ nanoparticles with varied concentrations for 24 h.
Figure S3 Liver and kidney toxicity (ALT, AST, CREA, and TBIL) assessment during the therapeutic process